BioMarin AAV gene therapy trial halted
The FDA has halted testing of BioMarin's AAV based gene therapy drug after liver cancer developed in treated mice. BioMarin's BMN_307...
top of page
News
Search
- Sep 7, 2021
CSO presented at CTGTAC
The Cellular, Tissue and Gene Therapies Advisory Committee held a virtual public meeting meeting on 2-3rd September on the toxicity risks...
- Sep 7, 2021
AAV Integration Roundtable
The ASGCT sponsored a roundtable event of talks by industry experts on AAV integration. These discussions were extremely interesting and...
- Aug 31, 2021
We have a new Principal Scientist
Saqlain Suleman has joined the TestAVec team as Principal Scientific Officer. He will be working to develop and lead projects in...
- Aug 31, 2021
Bluebird halts gene therapy trial
Bluebird Bio has halted a phase 3 gene therapy clinical trial against cerebral adrenoleukodystrophy. This trial use lentiviral vectors...
bottom of page